Fundraising Fox
/Companies
Sign in

Ocular Therapeutix

Bedford, US · Founded 2006 · 359 employees on LinkedIn · 5 known investors

Find your way into Ocular Therapeutix

Sign up to see every warm intro you have to Ocular Therapeutix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Ocular Therapeutix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Ocular Therapeutix was founded in 2006 by Amarpreet Sawhney.

ASAmarpreet Sawhney
Amarpreet SawhneyFounder
KH
Kevin HanleyExecutive
MGMichael Goldstein
Michael GoldsteinChief Strategy Advisor2022–2023Executive Officer at Ocular Therapeutix Nasdocul
DBDaniel Bollag
Daniel BollagExecutive
AMAntony Mattessich
Antony MattessichPresident and CEO2017–2024Executive Officer, Director at Ocular Therapeutix Nasdocul
DNDonald Notman
Donald NotmanChief Operating Officer and Chief Financial OfficerExecutive Officer at Ocular Therapeutix Nasdocul
PUPravin U. Dugel, MD
Pravin U. Dugel, MDExecutive Chairman, President, and CEO
JS
Jeffrey S. Heier, MDChief Scientific Officer
NK
Nadia K. Waheed, MD, MPHChief Medical Officer
PK
Peter K. Kaiser, MDChief Development Officer
PDPravin Dugel
Pravin DugelExecutive Chairman, President, and CEOPravin Dugel brings over 30 years of experience as a retina specialist, including previous roles as President of IVERIC Bio, Managing Partner of Retinal Consultants of Arizona and the Retinal Research Institute, and Clinical Professor at the USC Eye Institute. He currently serves as Executive Chairman, President, and CEO of Ocular Therapeutix.

Board

CWCharles Warden
Charles WardenBoard directorGeneral Partner at SV Health Investors

Investors · 5

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20Mvia Charles Warden · board

How we know: SV Health Investors's portfolio page · board seat on SEC Form D · Not right? Tell us

Top Corner Capitallisted by Top Corner CapitalBurlingame
Agent CapitalinferredWalthamvia Bruce Peacock · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$37.5M disclosed across 1 round · 2019

▶$37.5MraisedMar 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • W. James O'SheaDirector
  • Kevin HanleyExecutive Officer
  • Richard L. LindstromDirector
  • Michael GoldsteinExecutive Officer
  • Amarpreet SawhneyDirector
  • Daniel BollagExecutive Officer
  • Jeffrey S. HeierDirector
  • Antony MattessichExecutive Officer, Director
  • Donald NotmanExecutive Officer
  • Jaswinder ChadhaDirector
  • Charles WardenDirector
  • Bruce A. PeacockDirector
Offering amount
$37.5M
Amount sold
$37.5M
Finders' fees
$75K
Placement agents
Piper Jaffray & Co.
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Ocular Therapeutix went on to found or lead other companies.

Amar SawhneyChairmanFounded Access Closure +2Charles WardenDirectorFounded Aquea HealthJames BigginsEngineering Manager, New Product DevelopmentFounded Access VascularJaswinder ChadhaMember of the Board of DirectorsFounded Axtria

Frequently asked questions

What does Ocular Therapeutix do?
Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.
Who founded Ocular Therapeutix?
Ocular Therapeutix was founded by Amarpreet Sawhney in 2006.
Who are Ocular Therapeutix's investors?
Ocular Therapeutix's investors include Ascension Ventures, Sofinnova Ventures, SV Health Investors, Top Corner Capital, Agent Capital.
How much funding has Ocular Therapeutix raised?
Ocular Therapeutix has disclosed $37.5M raised across 1 round.
Where is Ocular Therapeutix headquartered?
Ocular Therapeutix is headquartered in Bedford, US.